Skip to main content

MarketPicks Buzzing Themes Headlines Earnings Leaders

YoursFeedNEW Portfolio Watch

SpikePanelPricing Terms Privacy Refunds Methodology Contact support@spikepanel.com

Market discussion analytics and AI summaries are for informational purposes only and are not financial, investment, tax, legal, or accounting advice.

$NVO — what investors on X are saying · SpikePanel

$NVO — investor discussion on X

Five-factor rating

Hold (sector percentile 50) — value A, growth C, profitability A, momentum D, revisions C. Updated daily, sector-relative, identical for every user.

Most active voices on $NVO

@himshouse · Hims House · 92 mentions · 44.9K followers
@thelonginvest · The Long Investor · 65 mentions · 273.4K followers
@tacticzh · TacticzHazel · 55 mentions · 39.1K followers
@dividendtalks · Dividend Talks on YouTube · 38 mentions · 79.0K followers
@bourboninsider · Bourbon Insider Research · 30 mentions · 13.6K followers
@tipranks · TipRanks · 28 mentions · 43.3K followers
@investinc_intel · Fundamental Investing · 26 mentions · 5.6K followers
@mind1nvestor · Mind Investor · 20 mentions · 40.8K followers
@aistocksavvy · Hardik Shah · 19 mentions · 40.1K followers
@patientinvestor · Patient Investor · 18 mentions · 58.2K followers

Recent headlines featuring $NVO

2026-08-10: Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose
2026-08-14: Eli Lilly's Oral Weight-Loss Drug Gets UK Approval, Intensifying Competition with Novo Nordisk
2026-08-12: Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47
2026-08-11: First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1
2026-08-05: Novo Nordisk Q2: Adjusted Sales Up 7%, GLP-1 Volume Supports but Prices Under Pressure
2026-08-08: Eli Lilly Officially Sets Q1 2027 FDA Filing for Retatrutide, Intensifying Weight-Loss Competition
2026-08-07: Texas Court Dismisses Strive Antitrust Suit Against Novo and Lilly
2026-08-05: Novo Nordisk wins Dutch preliminary injunction in semaglutide patent case
2026-08-05: Earnings report
2026-08-04: Lilly Offers Early Access to Retatrutide, Intensifying Obesity Drug Race
2026-08-03: Novo Nordisk to report earnings this week, focus on obesity drug competition
2026-08-01: Novo Nordisk’s ZEUS trial misses endpoint, erasing $30.7 billion as shares fall 10%

Market feed · Market voices · SpikePanel